Compliance, Adherence - Whatever, Just Put the D*mn Cream On...

The Captain of Compliance, The Admiral of Adherence... Whatever you want to call him, you're going to love this week's episode as the Derms on Drugs dig deep with Dr. Steve Feldman on how to help our patients actually follow through with our recommendations. Trust us, even if you've heard Dr. Feldman talk about this before, you're still not going to want to miss this.As part of our dive into the nitty gritty of adherence we'll also talk about:-The first "Oral Biologic" on the way from Janssen - is this oral peptide that inhibits IL-23 a real game changer?-How a drug like VTAMA is a game changer for pediatric atopic dermatitis, both because of how well it works and because it's so easy for patients to use-If Cabtreo, the new triple combo cream for acne, works so fast that it actually helps patients stick with using it Derms on Drugs is brought to you by ⁠⁠⁠Scholars in Medicine.⁠⁠Guest: Dr. Steven R. Feldman, MD, PhD is a Professor of Dermatology, Pathology, and Social Sciences & Health Policy at the Wake Forest School of Medicine. His chief clinical interest is psoriasis.  Feldman has done groundbreaking research on addiction to tanning beds, patients’ adherence to their medication treatment regimens, and patients’ satisfaction with their medical care.  Feldman’s experiences in medicine have led him to try to see how others perceive things, leading to his book Compartments and his recent novella Bent Toward Justice.  His research has been published in over 1,000 peer reviewed, Medline-referenced articles.  Expertscape.com ranks Feldman among the top experts in the world on psoriasis, acne, dermatology, and treatment adherence. Feldman also serves as the editor of the Journal of Dermatological Treatment and the Journal of Dermatology and Dermatological Surgery and as chief medical editor of The Dermatologist.  Resource links for this episode available at Scholars in Medicine:1.  FRONTIER-2: A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis2. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials3.  Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug4.  An exploratory study of adherence to topical benzoyl peroxide in patients with acne vulgaris5.  Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study6.  Long-term adherence to topical psoriasis treatment can be abysmal: a 1-year randomized intervention study using objective electronic adherence monitoring